

# CORRIGENDUM-1

S.No.	Clause	Representation	Amendment/Clarification
A. MACLEODS			
1.	Tender BOQ S.No 147 Levothyroxine 100 mcg (100 tab/bottle)	As per current tender product list Levothyroxine 100 mcg is required in pack of 100 tab bottle and in this regard we would like to inform you that most of companies are making this product pack of 120 tab bottle packing because of its dose regimen, So requesting you to approve both the pack size's (100 tab per bottle and 120 tab per bottle) this will enhance the number of bidder and you will get the most competitive price for the same.	No Change
2.	Tender BOQ S.No 148 Levothyroxine 25 mcg (100 tab/bottle)	As per current tender product list Levothyroxine 25 mcg is required in pack of 100 tab bottle and in this regard we would like to inform you that most of companies are making this product pack of 120 tab bottle packing because of its dose regimen, So requesting you to approve both the pack size's (100 tab per bottle and 120 tab per bottle) this will enhance the number of bidder and you will get the most competitive price for the same.	No Change

## CORRIGENDUM-1

3.	Tender BOQ S.No 149 Levothyroxine 50 mcg (100 tab/bottle)	As per current tender product list Levothyroxine 50 mcg is required in pack of 100 tab bottle and in this regard we would like to inform you that most of companies are making this product pack of 120 tab bottle packing because of its dose regimen, So requesting you to approve both the pack size's (100 tab per bottle and 120 tab per bottle) this will enhance the number of bidder and you will get the most competitive price for the same.	No Change
<b>B. SURGINEEDS</b>			
4.	Point No. 3 Page No. 23 Original Manufacturers or their sole authorized distributors/supplier having minimum average annual turnover of Rupees 120 crores and above or 10 crores and above respectively in the previous financial years/ last 3 years (PY- 2019-20, 2020-21, 2021-2022). It should be supported with documentary evidence in the form of certified audited balance sheet of the relevant period or supported with the certificate of Chartered Accountant indicating the	<p>The turnover condition of manufacture should be compulsory and instead of 120 crores, it should be 50 crores for better participation and to ensure quality drugs.</p> <p>We have done numerous govt. tender, there has never been any pre-condition on turnover of a distributor, such due-diligence should be left to manufacturers when they issue authority letter.</p> <p>We are attaching tender terms regarding turnover for HP state, IGMC Shimla and RPDMC Tanda for reference. You can clearly see, the focus is always on the turnover of manufacturer and never on distributor.</p>	<p><b>Amendment</b> In case the bidder is Original Manufacturers, the minimum average annual turnover should be Rupees 120 crores. In case the bidder is sole authorized distributors/supplier the minimum average annual turnover for distributor is Rupees 10 crores and for its all OEM 120 crores in the previous financial years/ last 3 years (PY- 2019-20, 2020-21, 2021-2022). However, in case of manufacturer of IV fluids the minimum turnover should be 50 crores only. It should be supported with documentary evidence in the form of certified audited balance sheet of the relevant period or supported with the certificate of Chartered Accountant indicating the detail</p>

# CORRIGENDUM-1

	detail of turn over for the relevant period.		of turn over for the relevant period.
C. PHARMA CRAFTS (INDIA)			
5.	Point No. 3 Page No. 23 Original Manufacturers or their sole authorized distributors/supplier having minimum average annual turnover of Rupees 120 crores and above or 10 crores and above respectively in the previous financial years/ last 3 years (PY- 2019-20, 2020-21, 2021-2022). It should be supported with documentary evidence in the form of certified audited balance sheet of the relevant period or supported with the certificate of Chartered Accountant indicating the detail of turn over for the relevant period.	<p>The turnover criteria of manufacturer (120cr) Or distributor(10cr) is very arbitrary. The clause should only be applicable on the manufacturer to ensure good quality drugs. A distributor with more than 10 cr. turnover can then quote products of small manufacturer to get the lowest rate.</p> <p>Since the supply quantity is meager for such bigger companies, the turnover criteria for manufacturers should be reduced to 50 crores to ensure better participation and continuous supplies.</p> <p>Turnover criteria for manufacturers (especially for IV fluids and others as well) should be reduced to 50 crore in line with most other states tender.</p>	Same as earlier
D. VAISHALI ENTERPRISES			
6.	Tender BOQ S.No 539	Kindly amend serial no 539. Iso - osmolar iodinated contrast agent(Non-ionic dimer) Lodixanol(320mg/ml) 100ml to Iso-osmolar iodinated contrast agent(Non-ionic dimer ) lodixanol(320mg/ml)100ml.	<p><b>Amendment</b></p> <p>Osmolar iodinated contrast agent(Non-ionic dimer) Lodixanol(320mg/ml) 100ml may be read as <u>Iso-osmolar iodinated contrast agent (Non-ionic dimer)</u> <u>lodixanol(320mg/ml)100ml.</u></p>
E. V.L.K HEALTH PRODUCT			
		<p>Clarification required on following points:</p> <p>1) Our registered office id located at Chandigarh from where we are already</p>	<p><b>Clarification</b></p> <p>1) Yes , the distributor from Chandigarh can participate in tender.</p>

## CORRIGENDUM-1

		<p>supplying drugs and medicines to several states. Shall we eligible to participate in the above mentioned tender being authorized distributor of our principle companies.</p> <p>2) Kindly clarify from whom the details are required as per appendix A. Is it from original manufacturer of their distributor? Is any supporting document is to be enclosed with it. Kindly brief what should be filled in the blank of detail of the location at which the local value addition was made?</p> <p>3) Kindly brief 80% or 50% as per clause one local supplier or class two local supplier or non local supplier is it % to tender quantity ?</p>	<p>2) The details of Original manufacturers is required in appendix A.</p> <p>3) Point D <u>Purchase Preference</u>, Page No. 26 of Tender document may be referred.</p>
--	--	---	--